GlassScriptPhysician profile
Tamara S Wilson
NPI 1841325503
$9,272.08
in general payments reported to CMS, 2019-2025
61 companies · $1,097 in 2025
The $1,097 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,045 · 2020: $1,392 · 2021: $1,352 · 2022: $1,684 · 2023: $1,555 · 2024: $1,147 · 2025: $1,097.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,799.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,799.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,960.26 | 2019-2025 | Vraylar, Ubrelvy, Qulipta |
| Amgen INC. | $1,218.00 | 2019-2025 | Repatha, Otezla, Repatha |
| Pfizer INC. | $809.78 | 2019-2025 | |
| Allergan, INC. | $485.73 | 2019-2020 | |
| Novo Nordisk INC | $420.51 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $414.91 | 2019-2025 | Breztri, Airsupra |
| Lilly USA, LLC | $373.73 | 2019-2025 | Mounjaro, Zepbound |
| Astellas Pharma US INC | $332.05 | 2019-2025 | Veozah |
| Glaxosmithkline, LLC. | $296.61 | 2019-2025 | Shingrix, Arexvy, Bexsero |
| Biohaven Pharmaceutical Holding Company LTD. | $236.62 | 2022 | |
| Eisai INC. | $219.90 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $213.11 | 2019-2024 | Gardasil 9, Gardasil, M-M-R II |
| Janssen Pharmaceuticals, INC | $175.29 | 2019-2023 | Spravato |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $162.19 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $145.61 | 2021-2025 | Rexulti |
Show all 61 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tamara Wilson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.